GC Biopharma announced on the 2nd that it has signed a contract for the processing of plasma derivatives with Solid Intellectual SDN BHD (SISB), a subsidiary of the Malaysian JAKEL Group.
SISB is a distribution affiliate of the pharmaceutical and medical device sector within the JAKEL Group. This contract resulted from a bid in March for a plasma processing project with the Malaysian health authorities, in which GC Biopharma participated with SISB.
This contract is a new award won by GC Biopharma for a project that has been exclusively carried out by the global pharmaceutical company CSL for about 15 years, marking the first time an Asian corporation has been selected as the sole contractor in this bid.
According to the contract, the Malaysian health authorities will supply plasma obtained through the National Blood Center to SISB, which will distribute the plasma to GC Biopharma. GC Biopharma plans to produce finished goods such as albumin and immunoglobulin from the plasma and export these back to SISB.
The company stated that it plans to supply at least $24 million (about 33 billion won) worth of blood products to Malaysia for a minimum of four years starting in 2026.
Lee Woo-jin, head of the global business division at GC Biopharma, noted, "We will continue to strengthen our position in the global market through strategic partnerships between countries."